English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose We compared the efficacy and safety of beinaglutide, aglucagon-like peptide-1 (GLP-1) analogue with metformin in lowering thebodyweight of patients who were overweight/obese and non-diabetic.  Patients and Methods Seventy-eight non-diabetic patients were randomlyselected and beinaglutide or metformin was administered for 12 weeks. Theprimary endpoints were changes in body weight and the proportions of patientswho lost≥5 and≥10% of their baseline body weights.  Results A total of 64 patients completed the study; patients in thebeinaglutide group exhibited more bodyweight loss than those in the metformingroup [(9.5±0.8%; 9.1±0.9 kg) and(5.1±0.9%; 4.5±0.8 kg), respectively,corresponding to a difference of approximately 4.5 kg (95%confidence interval, 2.2–6.9 kg; P&lt;0.01)]. In thebeinaglutide group, 90.6 and 40.6% of the patients lost≥5and≥10% of their body weight, respectively, whereas, in themetformin group, these rates were 46.9 and 12.5%, respectively(P&lt;0.01 and P&lt;0.05). Weight loss followingbeinaglutide treatment mainly resulted from the loss of fat mass. Compared tometformin, beinaglutide induced a greater decrease in the body mass index,weight circumference, percent body fat, and body fat mass (total, trunk, limb,android, and gynoid). Additionally, beinaglutide decreased serum insulin levelsand ameliorated insulin resistance.  Conclusions Beinaglutide is more efficient than metformin at reducingweight and fat mass in patients who are overweight/obese andnon-diabetic. Beinaglutide may be a useful therapeutic option foroverweight/obesity control in the Chinese population.

Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients